The Safer Alternative to $2.5B in Gadolinium Contrast Agents
Xeuj® — India's first patented iron-based nanoparticle MRI contrast agent. Pre-clinical validated. GMP & GLP done. MoU with PGIMER Chandigarh. Raising for clinical trials.
Why Xeuj® Is a Compelling Opportunity
A clinical-stage biotech with de-risked science, a massive unmet need, and a clear regulatory-commercial pathway.
Gadolinium Is Not Safe for Renal Patients
GBCAs used in ~40% of MRI scans carry an FDA Black Box Warning for Nephrogenic Systemic Fibrosis. EMA suspended linear agents. No safe alternative exists for 788M CKD patients worldwide.
Iron-Based, NSF-Free, Proven Safe
Patented iron nanoparticle formulation. Non-toxic (GLP & Genotoxicity certified). Green, aqueous one-pot synthesis. India's first 'Make in India' contrast agent. Granted patent (Ref no. 351940).
Ferabright™ FDA Approval Validates Approach
Oct 2025: FDA approved Ferabright™ (ferumoxytol) — first iron-based MRI contrast agent. This validates the entire iron nanoparticle platform. Xeuj® is positioned as next-generation with superior properties.
PGIMER Chandigarh — Trial Site Secured
MoU signed with Post Graduate Institute of Medical Education & Research — a 2,000+ bed premier institution. Ethics committee, infrastructure, and diverse patient population ready. This de-risks the #1 clinical trial hurdle.
$2.5 Billion and Growing
The global MRI contrast agents market is projected to reach $4.7B by 2032 (8.7% CAGR). India's market alone is growing at 7.4% CAGR from $87.8M to $144.9M by 2030.
138 Million Patients in India Need Xeuj®
India has the 2nd highest CKD burden globally with ~138M patients (The Lancet, 2023). These patients cannot safely receive gadolinium-based contrast due to NSF risk. Every one of them is a candidate for Xeuj®.
Xeuj® vs. The Field
Iron nanoparticle platform outperforms GBCAs on safety, cost, and regulatory risk.
Achieved on Zero External Funding
Every milestone reached through grants, founder equity, and disciplined capital management.
Use of Funds & Path to Profitability
Capital allocation for clinical trials and the projected revenue trajectory.
Use of Funds
Revenue Projection
Dr. Madhulekha Gogoi
Founder, Director & CEONanotechnologist with 12+ years of research experience. PhD from Tezpur University, post-doc at IIT Guwahati and CSIR-NEIST. Recipient of BIRAC BIG grant, multiple DST fellowships. 11+ publications, 3 book chapters, granted Indian patent.
"We have the science, the partnership, and the execution plan. We need capital to complete clinical trials and bring this to patients."View Full Team
Multiple Exit Paths
Clear routes to liquidity with strong precedent in the contrast agent space.
Strategic Acquisition
Targets: Bayer, Bracco, Guerbet, GE. Multiple: 4-8× revenue. Precedent: Bayer + Attralus (Jan 2026).
Licensing & Royalties
License international rights for upfront + milestones + 8-15% royalties. Retain India market for direct sales.
IPO
Post-commercial launch on BSE/NSE or NASDAQ via ADR. Indian biotech IPOs command 25-40× PE.
Invest in the Future of Safer MRI
Your investment will directly impact millions of patients who need safer contrast options. Let's build the future of diagnostics together.